It’s not the fittest or the most intelligent, it’s those who are most willing to adapt to change that will survive.
OXGENE, the new trading name of Oxford Genetics Ltd
OXGENE finds solutions to seemingly impossible problems. Our unique combination of precision engineering and breakthrough science, together with advanced robotics and bioinformatics, accelerates the rational design, discovery and manufacture of cell and gene therapies.
We work at the very edge of impossible. We solve the problem of high-titre, scalable virus manufacture for gene therapy treatments. We address the challenge of speed and robustness in gene editing with our high throughput, automated CRISPR platform. We use our novel mammalian display technology to discover antibodies against previously intractable membrane proteins.
We redefine ‘possible’ in mammalian cell engineering.
OXGENE accelerates the discovery and production of cell and gene therapies, addressing key industry bottlenecks and facilitating new therapeutic approaches
We offer our expertise for custom projects to solve challenges in the advancement of drug discovery and development, and we collaborate to bring new solutions to market as efficiently as possible.
Our scientists are experts in their field and invest time in understanding the challenges and priorities that shape a custom project. We then continue to support our customers throughout solution design and project delivery, as well as through process development, method transfer, and implementation.
Our licensable platform technologies are an essential element of our portfolio and we are constantly innovating to ensure that we can provide the robust tools needed to reduce the timeframe from drug discovery to market approval. Our investment in automation means we can provide robust, reliable and repeatable solutions to some of the most complex processes in the industry today.